CVRx Inc. launches a European registry to track treatment with its Barostim neo heart implant for patients with drug-resistant hypertension.
MASSDEVICE ON CALL — Minneapolis-based CVRx Inc. launched a European registry to track treatment with its Barostim neo device, a heart implant for treatment of drug-resistant hypertension.
The Barostim neo device is designed to trigger the body's natural blood flow regulation system by activating the baroreceptors, located in the carotid artery, which regulate cardiovascular function.
The stimulation effectively tells the arteries to relax, the heart to slow down and the kidneys to reduce fluid in the body, resulting in reduced cardiac exertion, reducing the workload on the heart, according to a press release.
The new registry is expected to enroll up to 500 patients and track performance outcomes and physician experience.
MicroVention launches study of coiling technologies for brain aneurysms
Tustin, Calif.-based MicroVention began enrollment in a clinical trial comparing coiling technologies used to treat intracranial aneurysms.
The prospective, randomized, international multicenter trial will enroll up to 600 subjects in a study pitting new generation MicroVention hydrogen coils against bare platinum coils.
New stented aortic bioprosthesis delivers outstanding implantability and performance.
Italian device maker Sorin Group lands European regulatory approval for its next-generation Crown PRT...
Ocular Therapeutix prices its initial public offering at $13 per share, a dollar below its prior...
Covidien's fiscal 3rd-quarter sales come in dead even with expectations on Wall Street as its...
Minnesota medical device maker Medtronic estimates that China could soon account for 20% of the...